EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Dual-target EZH2 inhibitor: latest advances in medicinal chemistry

Lai Wei, Dan Mei, Sijia Hu, Shufang Du iD

Future Medicinal Chemistry · 02.08.2024 · 16 (15) · 1561-1582

DOI: 10.1080/17568919.2024.2380243 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Future Medicinal Chemistry, online erschienen am 31.07.2024. Verfasst von Lai Wei und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of…. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, plays a crucial role in tumor progression by regulating gene expression. EZH2 inhibitors have emerged as promising anti-tumor agents due to their potential in cancer treatment strategies. However, single-target inhibitors often face limitations such as drug resistance and side effects. Dual-target inhibitors, exemplified by EZH1/2 inhibitor HH-2853(28), offer enhanced efficacy and reduced adverse effects. This review highlights recent advancements in dual inhibitors targeting EZH2 and other proteins like BRD4, PARP1, and EHMT2, emphasizing rational design, structure-activity relationships, and safety profiles, suggesting their potential in clinical applications. [Box: see text].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinHumansAntineoplastic AgentsNeoplasmsStructure-Activity RelationshipChemistry, PharmaceuticalEnzyme InhibitorsAnimalsTranscription Factors

Stichwörter der Autor:innen

ARBMI1DNMTsEHMT2 (G9a)EZH2EZH2 inhibitorsdrug designstructure–activity relationship

Substanzen

Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanAntineoplastic AgentsEnzyme InhibitorsTranscription Factors

Autor:innen und Institutionen

  • State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology Department of Orthodontics, Sichuan University, Chengdu,…

ORCID-Profile: Shufang Du

Zitieren

APA

Wei, L., Mei, D., Hu, S., & Du, S. (2024). Dual-target EZH2 inhibitor: latest advances in medicinal chemistry. Future Medicinal Chemistry, 16(15), 1561-1582. https://doi.org/10.1080/17568919.2024.2380243

Vancouver

Wei L, Mei D, Hu S, Du S. Dual-target EZH2 inhibitor: latest advances in medicinal chemistry. Future Medicinal Chemistry. 2024;16(15):1561-1582. doi:10.1080/17568919.2024.2380243

BibTeX
@article{Wei2024,
  author = {Wei, Lai and Mei, Dan and Hu, Sijia and Du, Shufang},
  title = {Dual-target EZH2 inhibitor: latest advances in medicinal chemistry},
  journal = {Future Medicinal Chemistry},
  year = {2024},
  volume = {16},
  number = {15},
  pages = {1561--1582},
  doi = {10.1080/17568919.2024.2380243}
}
Kostenlos starten →